Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5540938	ACORDA	Formulations and their use in the treatment of neurological diseases	Jul, 2018 (5 years ago)
US9918973	ACORDA	Sustained release aminopyridine composition	Dec, 2024 (7 months from now)
US8663685	ACORDA	Sustained release aminopyridine composition	Jan, 2025 (8 months from now)
US8440703	ACORDA	Methods of using sustained release aminopyridine compositions	Apr, 2025 (11 months from now)
US8354437	ACORDA	Method of using sustained release aminopyridine compositions	Dec, 2026 (2 years from now)
US8007826	ACORDA	Sustained release aminopyridine composition	May, 2027 (3 years from now)

Ampyra is owned by Acorda.

Ampyra contains Dalfampridine.

Ampyra has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Ampyra are:

Ampyra was authorised for market use on 22 January, 2010.

Ampyra is available in tablet, extended release;oral dosage forms.

Ampyra can be used as improvement of walking in patients with multiple sclerosis (ms).

Drug patent challenges can be filed against Ampyra from 22 January, 2014.

The generics of Ampyra are possible to be released after 26 May, 2027.

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Jan 22, 2017
New Chemical Entity Exclusivity(NCE)	Jan 22, 2015

NCE-1 date: 22 January, 2014

Market Authorisation Date: 22 January, 2010

Treatment: Improvement of walking in patients with multiple sclerosis (ms)

Dosage: TABLET, EXTENDED RELEASE;ORAL

Ampyra patents expiration